A VS GEHC Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

A
29/100

A returned -20.34% in the last 12 months. Based on SPY's performance of -16.79%, its performance is below average giving it a score of 28 of 100.

GEHC
100/100

GEHC returned 33.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

A
82/100

14 analysts offer 12-month price targets for A. Together, they have an average target of 167.75, the most optimistic target put A at 170 within 12-months and the most pessimistic has A at 161.

GEHC
10/100

1 analysts offer 12-month price targets for GEHC. Together, they have an average target of 0, the most optimistic target put GEHC at 0 within 12-months and the most pessimistic has GEHC at 0.

Sentiment

A
69/100

A had a bullish sentiment score of 69.50% across Twitter and StockTwits over the last 12 months. It had an average of 77.66 posts, 409.66 comments, and 1,364.19 likes per day.

GEHC

"Sentiment" not found for GEHC

Technicals

A
50/100

A receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

GEHC
75/100

GEHC receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

Earnings

A
100/100

A has missed earnings 0 times in the last 20 quarters.

GEHC
100/100

GEHC has missed earnings 0 times in the last 20 quarters.

Profit

A
79/100

Out of the last 20 quarters, A has had 20 profitable quarters and has increased their profits year over year on 10 of them.

GEHC
51/100

Out of the last 8 quarters, GEHC has had 8 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

A
52/100

A has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

GEHC
59/100

GEHC has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

Dividend

A
48/100

A's most recent dividend was $0.15 per share, based on a share price of $109.02. It was a payout ratio of 24.10% compared to their total earnings.

GEHC
10/100

GEHC's most recent dividend was $0.03 per share, based on a share price of $72.21. It was a payout ratio of 3.35% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Agilent Technologies Inc. Summary

New York Stock Exchange / A
Healthcare
Medical - Diagnostics & Research
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

GE HealthCare Technologies Inc. Common Stock Summary

Nasdaq / GEHC
Healthcare
Medical - Healthcare Information Services
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.